PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced that it has launched Eszopiclone
Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion
Pharmaceuticals Inc.'s Lunesta®. Mylan received final
approval from the U.S. Food and Drug Administration (FDA) for its
Abbreviated New Drug Application (ANDA) for this product, which is
indicated for the treatment of insomnia.
Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of
approximately $851.8 million for the
12 months ending Dec. 31, 2013,
according to IMS Health.
Currently, Mylan has 187 ANDAs pending FDA approval representing
$94.9 billion in annual brand sales,
according to IMS Health. Forty-two of these pending ANDAs are
potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12
months ending Dec. 31, 2013,
according to IMS Health. When including ANDAs associated with
Mylan's recent acquisition of Agila, the company now has a total of
304 ANDAs pending FDA approval.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.